BioStem (BSEM) Director Rayna Lesser Hanaway Converts 7,671 RSUs

What Happened

• Rayna Lesser Hanaway, a director of BioStem Technologies, had 7,671 restricted stock units (RSUs) vest and converted those units into 7,671 shares of common stock on August 27, 2026. The Form 4 shows an acquisition via conversion/exercise (transaction code M) of 7,671 shares at $0.00 per share.
• The filing also reports a corresponding derivative disposition of 7,671 shares (also coded M) at $0.00. Footnotes state each RSU equals a contingent right to one share and that the RSUs vested on August 27, 2026. The filing was submitted on August 28, 2026.

Key Details

• Transaction date: August 27, 2026; Form 4 filed August 28, 2026 (timely).
• Acquired: 7,671 shares via conversion/exercise of RSUs at $0.00 per share.
• Disposed (derivative): 7,671 units at $0.00 per share (filing lists a derivative disposition; purpose not specified in the form).
• Footnotes: F1 — each RSU converts to one share; F2 — RSUs vested on Aug 27, 2026.
• Exhibit noted: Exhibit 24 — Power of Attorney.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This was not a cash purchase or sale on the open market; it reflects RSUs vesting and converting into common shares (a common form of executive/director compensation).
• Conversions at $0.00 per share indicate receipt of vested compensation rather than a market purchase. The reported derivative disposition may reflect internal settlement/administrative mechanics; the form does not state a sale for cash or tax-withholding details.